EUCAST technical note on posaconazole

Clinical Microbiology and Infection

Volumn 17, Issue 11, 2011, Pages

  Arendrup, M C ^a   Cuenca Estrella, M ^b   Donnelly, J P ^c   Hope, W ^d   Lass Florl C ^e   Rodriguez Tudela, J L ^b  

^a STATENS SERUM INSTITUT   (Denmark)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Breakpoints; Candida; EUCAST Technical Note; Posaconazole; Susceptibility testing

Indexed keywords

POSACONAZOLE;

ADVISORY COMMITTEE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDIASIS; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG CHOICE; EPIDEMIOLOGICAL DATA; HUMAN; JOB EXPERIENCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; SPECIES DIFFERENCE;

CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS;

EID: 80054064322     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2011.03646.x     Document Type: Article

References (6)

1. Skiest DJ, Vazquez JA, Anstead GM et al. Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. Clin Infect Dis 2007; 44: 607-614.
2. Vazquez JA, Skiest DJ, Nieto L et al. A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin Infect Dis 2006; 42: 1179-1186.
3. Vazquez JA, Skiest DJ, Tissot-Dupont H, Lennox JL, Boparai N, Isaacs R. Safety and efficacy of posaconazole in the long-term treatment of azole-refractory oropharyngeal and esophageal candidiasis in patients with HIV infection. HIV Clin Trials 2007; 8: 86-97.
4. Krishna G, Sansone-Parsons A, Martinho M, Kantesaria B, Pedicone L. Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. Antimicrob Agents Chemother 2007; 51: 812-818.
5. Krishna G, Moton A, Ma L, Medlock MM, McLeod J. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother 2009; 53: 958-966.
6. Krishna G, Ma L, Vickery D et al. Effect of varying amounts of a liquid nutritional supplement on the pharmacokinetics of posaconazole in healthy volunteers. Antimicrob Agents Chemother 2009; 53: 4749-4752.